An interventional study of SCBT and SSRIs and/or SNRIs in Generalized Anxiety Disorder and Major Depressive Disorder, sponsored by Shanghai Mental Health Center. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-11-01.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Generalized Anxiety Disorder with a site in China — 16 open to participants now, 16 under way, 3 of them phase 3. Generalized Anxiety Disorder · China.
Among the 23 studies in Generalized Anxiety Disorder with a site in China, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2017, is one of 11 with no phase, and was the 4th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →16 of the 23 studies in Generalized Anxiety Disorder with a site in China are open now. Recruiting first, the newest first:
Lishu Gao · Sites in China
Ages 18–60 · Healthy volunteers
Fudan University · Sites in China
Ages 18–70 · Women only
Anhui Medical University · Sites in China
Ages 18+
WANG KAI · Sites in China
Ages 18–60
Xijing Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 122 across the 20 interventional studies, 120 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
Shanghai Mental Health Center is the lead sponsor of 272 studies on the registry; 91 are open to participants now.
Shanghai Mental Health Center has 2 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
5 of the studies in Generalized Anxiety Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07330648Anhui Medical UniversityProspective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder | 2027-01-31 |
| NCT07909200Central South UniversityTemporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder | 2027-03-01 |
| NCT07403591Anhui Medical UniversityMapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder | 2027-03-01 |
| NCT07290153Fudan UniversityPsychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC | 2027-06-30 |
| NCT07392645Lishu GaoElectroacupuncture for Generalized Anxiety Disorder: Clinical Efficacy and Neuroimaging Mechanisms | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Generalized Anxiety Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial attempts to evaluate the treatment efficacy of Simplified Cognitive Behavioral Therapy (SCBT) and its safety among schizophrenia patients. Half of participants will be randomized to accept SCBT.
The investigators have developed a simplified but standardized set of cognitive behavioral treatment (including the therapist's manual and patient self-help manual) for the patients of generalized anxiety disorder and depression, known as Simplified Cognitive Behavioral Therapy (SCBT). SCBT is the main psychological intervention of this study. The aim of this study is to verify its efficacy and applicability using a multi-center, randomized, placebo controlled and single-blind design, and to optimize the treatment program. The investigators hypothesize that SCBT is effective in patients with depression or anxiety, and the manual is easily-operated for the therapists.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
Behavioral: SCBT · Drug: SSRIs and/or SNRIs
Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
Drug: SSRIs and/or SNRIs · Behavioral: Psychological Placebo
Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
Drug: SSRIs and/or SNRIs
changes of The Hamilton Depression Scale (HAMD-17)
Scale total range is 52. Lower score represents a better outcome.
Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
changes of The Hamilton Anxiety Scale (HAMA-14)
Scale total range is 56. Lower score represents a better outcome.
Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
changes of The Patient Health Questionnaire (PHQ-9)
Scale total range is 27. Lower score represents a better outcome.
Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
changes of The GAD-7
Scale total range is 21. Lower score represents a better outcome.
Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
changes of The Mos 36-item Short Form Health Survey (SF-36)
It has nine dimensions, each dimension has an independent fractional formula.
Time frame: At baseline, 4-week, 8-week, 12-week, 20-week, 32-week and 56-week.
changes of Treatment Emergent Symptom Scale (TESS)
Evaluation of side effects caused by various psychotropic drugs.
Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
changes of Clinical Global Impression (CGI)
Evaluation of clinical efficacy. Lower score represents a better outcome.
Time frame: At baseline, 2-week, 4-week, 6-week, 8-week, 12-week, 20-week, 32-week and 56-week.
Plan to share: No — No plan to share IPD data
No publications or documents are linked to this record.
Started Jul 2017 (actual). Primary completion is estimated for Mar 2018, 8 months after the start.
Of 174 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 55. This study's planned 8 months is below that.
Counting every sponsor, half of 183 studies reached it within 28 months; a quarter within 15 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →
Shanghai Mental Health Center →